

Almirall announces multi-target licensing agreement with Ablexis and collaboration with AlivaMab Discovery Services to accelerate antibody drug discovery and development

- Through this license agreement with Ablexis, Almirall is granted rights to use the AlivaMab[®] Mouse technology for research, development, and commercialisation of antibodies
- AlivaMab Mouse offers state-of-the-art transgenic mouse platforms delivering high-diversity human therapeutic antibodies
- Almirall will partner with AlivaMab Discovery Services (ADS) to perform the drug discovery research, leveraging the ADS team's expertise in antibody drug discovery and engineering

BARCELONA, Spain and SAN DIEGO, Calif., USA, January 31, 2022 – Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced a multi-target licensing agreement with **Ablexis, LLC**, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, and a research collaboration with **AlivaMab Discovery Services, LLC**, a leader in the discovery and engineering of antibody therapeutics.

Under the terms of the license, Almirall is granted non-exclusive rights to use Ablexis' AlivaMab Mouse technology for the discovery, development, and commercialization of innovative antibody drugs.

In addition, Almirall will collaborate with AlivaMab Discovery Services to conduct the research, leveraging ADS' expertise in antibody drug discovery and engineering using the AlivaMab Mouse technology, a state-of-art platform for the generation of human therapeutic antibodies.

"These agreements are in line with Almirall's vision to develop innovative treatment options for patients suffering from severe skin diseases. AlivaMab Discovery Services' profound know-how in antibody discovery and engineering together with Almirall's expertise in dermatology will strongly accelerate the development of differentiated treatments to help patients get closer to their goal of leading a healthy life," stated **Dr. Thomas Huber, Research Director at Almirall**. "The agreements highlight the company's commitment to early biologics discovery to provide the best solutions to skin conditions through novel science."

"We are pleased that Almirall has selected the AlivaMab Mouse technology as a key platform for its antibody drug discovery," said **Larry Green, Chief Executive Officer, Ablexis, LLC**. "Together with the talented and highly experienced team of antibody drug hunters at Ablexis' sister company, AlivaMab Discovery Services, we are increasingly recognized by partners with real experience in antibody drug discovery and development."

“Almirall joins our rapidly expanding list of high-quality partners that leverage the discovery, engineering and developability assessment capabilities of ADS, especially for challenging targets, functional design goals and advanced modalities,” said **Justin Mika, Chief Executive Officer at AlivaMab Discovery Services**. “Our partners appreciate how our team’s expertise, combined with the proven AlivaMab Mouse platform, significantly improves the probability of success and shortens timelines in discovery and development. We look forward to supporting Almirall’s efforts to help patients with dermatological conditions.”

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient’s needs through science to improve their lives. Our Noble Purpose is at the core of our work: “Transform the patients’ world by helping them realize their hopes and dreams for a healthy life”. We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 78-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2020 were 814.5 million euros.

For more information, please visit almirall.com

About Ablexis, LLC

Ablexis, LLC created and non-exclusively licenses AlivaMab Mouse, a suite of unique, patented next generation transgenic mice, as a platform for human therapeutic antibody discovery. Ablexis has license agreements with dozens of companies, including global pharmaceutical companies, public and private biotechnology companies and other entities. Ablexis continues making AlivaMab Mouse available via non-exclusive licenses.

For more information, visit www.ablexis.com or email info@ablexis.com

About AlivaMab Discovery Services

AlivaMab Discovery Services (ADS) sets its partners’ antibody discovery programs on the fastest and most de-risked path through discovery and development. Trusted by top-tier pharmaceutical and biotechnology companies, ADS delivers drug-quality, fully human antibodies on exceptional timelines. ADS achieves its partners’ design goals, from simple to extraordinarily challenging, through the generation and function-first screening of large, molecularly diverse panels of antibodies. ADS focuses on rapid and efficient delivery of antibodies, characterized for function, kinetics and developability, and engineering for advanced modalities, including multispecifics and CARs. The ADS team’s experience in antibody drug discovery and development comes from many of the world’s top 15 pharmaceutical companies, including AbbVie, AstraZeneca, Bristol Myers Squibb, Novartis, Pfizer and Roche/Genentech, and translates across more than 500 discovery programs and 35 clinical candidates. This experience, combined with the use of trusted, proven technologies, including Ablexis’ AlivaMab® Mouse platforms, ensures the highest probability of success.

For more information, please visit www.alivamab.com or email info@alivamab.com

Almirall:

Media contact:

Tinkle
Laura Blázquez
lblazquez@tinkle.es
Phone: (+34) 600 430 581

Investors’ Relations contact

Almirall
Pablo Divasson del Fraile
pablo.divasson@almirall.com
Phone: (+34) 93 291 3087

Corporate Communications contact:

Almirall
Maria Duro
maria.duro@almirall.com
Phone: (+34) 671 580 492

AlivaMab Discovery Services:

Media contact:

Stacey Borders
sborders@alivamab.com
Phone: (858) 252-3420 x105

BD contact

info@alivamab.com

Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.

If you wish to unsubscribe from any Almirall Corporate communication, click [here](#).

In accordance with the General Data Protection Regulation and the applicable local regulations, we inform you that your personal data is processed by Almirall S.A. with registered address at Ronda del General Mitre 151, -08022-, Barcelona (Spain), acting as Controller in line with the purposes indicated in our Privacy Policy. For further information, you may consult it at <https://www.almirall.com/privacy-policy> or contact our Data Protection Officer at the e-mail address: dpo.global@almirall.com. PRNewswire is the Agency that licenses your personal data according to their privacy policy <https://gdpr.cision.com/gdpr>. At any time you can exercise your rights of access, rectification, deletion, objection, portability as well as the limitation of the processing of your data in the terms provided in the current regulations on Data Protection, by addressing the corresponding written request to our postal address (Ronda General Mitre, 151, 08022 Barcelona, Spain). The request to exercise any of your rights must be accompanied by a copy of an official document that identifies you (ID, driver's license or passport). Finally, we inform you that you can contact the Spanish Data Protection Agency and any other competent public bodies for any claim arising from the processing of your personal data.